University of Leicester
Browse
lawson_2018_oi_180236.pdf (888.01 kB)

Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease.

Download (888.01 kB)
journal contribution
posted on 2019-05-20, 11:20 authored by CA Lawson, MA Mamas, PW Jones, L Teece, G McCann, K Khunti, UT Kadam
Importance: In heart failure (HF), chronic obstructive pulmonary disease (COPD) increases the risk of poor outcomes, but the effect of COPD severity is unknown. This information is important for early intervention tailored to the highest-risk groups. Objectives: To determine the associations between COPD medication intensity or stage of airflow limitation and the risk of hospitalization or death in patients with HF. Design, Setting, and Participants: This UK population-based, nested case-control study with risk-set sampling used the Clinical Practice Research Datalink linked to Hospital Episode Statistics between January 1, 2002, to January 1, 2014. Participants included patients aged 40 years and older with a new diagnosis of HF in their family practice clinical record. Data analysis was conducted from 2017 to 2018. Exposures: In patients with HF, those with COPD were compared with those without it. International COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD]) guidelines were used to stratify patients with COPD by 7 medication intensity levels and 4 airflow limitation severity stages using automatically recorded prescriptions and routinely requested forced expiratory volume in 1 second (FEV1) data. Main Outcomes and Measures: First all-cause admission or all-cause death. Results: There were 50 114 patients with new HF (median age, 79 years [interquartile range, 71-85 years]; 46% women) during the study period. In patients with HF, COPD (18 478 [13.8%]) was significantly associated with increased mortality (adjusted odds ratio [AOR], 1.31; 95% CI, 1.26-1.36) and hospitalization (AOR, 1.33; 95% CI, 1.26-1.39). The 3 most severe medication intensity levels showed significantly increasing mortality associations from full inhaler therapy (AOR, 1.17; 95% CI, 1.06-1.29) to oral corticosteroids (AOR, 1.69; 95% CI, 1.57-1.81) to oxygen therapy (AOR, 2.82; 95% CI, 2.42-3.28). The respective estimates for hospitalization were AORs of 1.17 (95% CI, 1.03-1.33), 1.75 (95% CI, 1.59-1.92), and 2.84 (95% CI, 1.22-3.63). Availability of spirometry data was limited but showed that increasing airflow limitation was associated with increased risk of mortality, with the following AORs: FEV1 80% or more, 1.63 (95% CI, 1.42-1.87); FEV1 50% to 79%, 1.69 (95% CI, 1.56-1.83); FEV1 30% to 49%, 2.21 (95% CI, 2.01-2.42); FEV1 less than 30%, 2.93 (95% CI, 2.49-3.43). The strength of associations between FEV1 and hospitalization risk were similar among stages ranging from FEV1 80% or more (AOR, 1.48; 95% CI, 1.31-1.68) to FEV1 less than 30% (AOR, 1.73; 95% CI, 1.40-2.12). Conclusions and Relevance: In the UK HF community setting, increasing COPD severity was associated with increasing risk of mortality and hospitalization. Prescribed COPD medication intensity and airflow limitation provide the basis for targeting high-risk groups.

Funding

The study was supported by grant NIHR-DRF-2012-05-288 from the National Institute for Health Research (NIHR) doctoral fellowship; the NIHR Collaboration for Leadership in Applied Health Research and Care–East Midlands; the NIHR Leicester–Loughborough Diet, Lifestyle, and Physical Activity Biomedical Research Centre, which is a partnership between University Hospitals of Leicester National Health Service Trust, Loughborough University, and the University of Leicester; and award 204801/Z/16/Z from Leicester–Wellcome Trust Institutional Strategic Support Fund Fellowship.

History

Citation

JAMA Network Open, 2018, 1 (8), e185489

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences

Version

  • VoR (Version of Record)

Published in

JAMA Network Open

Publisher

JAMA Network

eissn

2574-3805

Acceptance date

2018-10-15

Copyright date

2018

Available date

2019-05-20

Publisher version

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2718091

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC